Pharmaceuticals Sector - Solvay

More documents

Recommendations

Info

30 “ The creation of a new ‘Molecular Solutions’ Strategic Business Unit is a fi rst concrete step in this direction.” Solvay Global Annual Report 2005 The “Organic” cluster: Molecular Solutions To speed up its growth, the Sector created in 2005 a new activity cluster, aimed at developing new high-added-value lines of products with high know-how content intended for very advanced markets. The creation of a new “Molecular Solutions” Strategic Business Unit is a fi rst concrete step in this direction. The new SBU will consolidate its activities around: – Solvay’s majority shareholding in Girindus (with units at Bensberg and Künsebeck, Germany and in the USA), which was acquired in a friendly takeover bid approved by a majority of shareholders and announced on August 24, 2005. Girindus is a specialist research company that manufactures and develops a portfolio of Specialties and of specifi c chemical processes. Girindus has developed unique chemical processes, in particular for producing oligonucleotides, which are active compounds used in the treatment of genetic diseases and as active ingredients in certain niche cosmetics. – Peptisyntha (with units at Neder-over-Heembeek, Belgium and Torrance, California, USA), a specialist in peptide synthesis. This will permit the development of high-added-value synergies with Girindus in oligonucleotides and oligopeptides. – The fl uorinated organic chemicals activities of the Fluor SBU, including the Bad Wimpfen (Germany) facility. – The fi ne chemistry unit of Solvay Spécialtés France at Salin-de- Giraud (France) – A fi ne chemicals commercial and trading unit currently at Suresnes (France). The new Molecular Solutions SBU should rapidly become fi nancially autonomous and will in the medium term achieve the size and dynamism to exploit these activities in a profi table and sustainable way. The Molecular Solutions SBU is headquartered at Bensburg, close to Cologne (Germany). In 2005 the Sector created two market-oriented “Solution Units” Again in order to generate growth, the Sector decided to boost its search for new activities by focusing on a horizontal, marketdirected approach, with greater emphasis on Specialities. Following the creation in 2003 of the Chemicals Business Deployment team (CBD) to strengthen knowledge of selected markets and contribute to profi table growth in the Sector by proposing cross-SBU initiatives directed at Chemicals Sector high-added-value products, two “Solution Units” were created in 2005. A Solution Unit is a group of employees from various Strategic Business Units (SBUs) who focus on a specifi c market. By combining offerings, this team should considerably improve their market knowledge and customer proximity. It should also better serve the market, increase profi tability and propose a strategy for growth. The “Health Care Inorganics” Solution Unit will group our offerings in the pharmaceuticals and cosmetics fi elds, proposing products like sodium bicarbonate (dialysis excluded), soda ash, precipitated sodium carbonate, magnesium compounds, caustic soda, hydrochloric acid, hydrogen peroxide, peracetic acid and sodium fl uoride. The two “partner SBUs” of this Solution Unit, centred at Angera (Italy), will be Soda Ash and Advanced Functional Minerals. The “Soil Remediation Reagents” Solution Unit will develop our sales of a range of products for the in situ remediation of polluted soils, with a combination of bio-remediation and chemical oxidation. The idea is to replicate in Europe an initial fruitful experiment in the USA and make full use of the considerable expertise of the HSE (Health, Safety and Environment) Competence Centre of our Central Research and Technology Management. Initially this Solution Unit will offer calcium and magnesium peroxides, sodium percarbonate and hydrogen peroxide, to be followed by other reagents in the near future. This Solution Unit will be established in Brussels with Detergents and Hydrogen Peroxide as its SBU partners.
“ The ‘Soil Remediation Reagents’ Solution Unit will develop our sales of a range of products for the in situ remediation of polluted soils.” Chemicals 31 Solvay Global Annual Report 2005
Page 1 and 2: Driven by the future Growth, Compet
Page 3 and 4: Highlights January 2005 Solvay fi n
Page 5 and 6: Activities Group sales 2005 = EUR 8
Page 7 and 8: Our Vision - Independent industrial
Page 9 and 10: here to stay, in our view irreversi
Page 11 and 12: Board of Directors and Corporate Go
Page 13 and 14: 4 Executive Committee and General M
Page 15 and 16: Such a strategy is possible only wi
Page 17 and 18: Specialities Solvay Specialties fro
Page 19 and 20: Key fi gures [EUR million] Pharmace
Page 21 and 22: Cardiometabolic Cardiovascular dise
Page 23 and 24: Cardiometabolics Fenofi brate, TRIC
Page 25 and 26: “ DUODOPA® entered Solvay’s pr
Page 27 and 28: Pharmaceuticals Sector Therapeutic
Page 29 and 30: Key fi gures [EUR million] Chemical
Page 31 and 32: Growth To speed up its growth, the
Page 33: Initiatives have also been launched
Page 37 and 38: Key fi gures [EUR million] Plastics
Page 39 and 40: Innovation “Twin-Sheet Blow Mould
Page 41 and 42: Plastics 37 Solvay Global Annual Re
Page 43 and 44: which it was able to take advantage
Page 45 and 46: New Business Development Priority t
Page 47 and 48: Meeting The Science Days organized
Page 49 and 50: Human Resources The Group’s fi ve
Page 51 and 52: “ At the end of this seminar, all
Page 53 and 54: Sustainable Development 2005 saw th
Page 55 and 56: Accident frequency rate Persons wor
Page 57 and 58: Management Report New records for S
Page 59 and 60: Expenditure on the future by Sector
Page 61 and 62: Financial Statements The following
Page 63 and 64: Consolidated balance sheet EUR mill
Page 65 and 66: IFRS valuation rules The main accou
Page 67 and 68: 9. Impairment Every year the Group
Page 69 and 70: Notes to the fi nancial statements
Page 71 and 72: (2) Financial data by region These
Page 73 and 74: and the estimated fi nancial conseq
Page 75 and 76: The deferred taxes recorded in the
Page 77 and 78: 2005 Millions EUR Acquisitions Disp
Page 79 and 80: Neopharma On January 19, 2005 the S
Page 81 and 82: (around 300 persons) with a view to
Page 83 and 84: In 2005 the impairment tests on goo
Page 85 and 86:
Solvay Group purchased 100% of the
Page 87 and 88:
Post-employment benefi t plans are
Page 89 and 90:
Actuarial assumptions used in deter
Page 91 and 92:
Analysis of total fi nancial debt b
Page 93 and 94:
In this way, at the end of 2005, th
Page 95 and 96:
The following amounts relating to J
Page 97 and 98:
PORTUGAL Fournier Farmaceutica Port
Page 99 and 100:
List of fully consolidated Group co
Page 101 and 102:
Solvay Salz Holding GmbH, Hannover
Page 103 and 104:
CANADA Fournier Pharma, Inc., Montr
Page 105 and 106:
GREAT BRITAIN Inergy Automotive Sys
Page 107 and 108:
Summary fi nancial statements of So
Page 109 and 110:
Statutory auditor’s report to the
Page 111 and 112:
The Solvay share compared with the
Page 113 and 114:
Contacts: The Investor Relations Te
Page 115 and 116:
Shareholders’ Diary - May 9, 2006
show all

Pharmaceuticals Sector - Solvay

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?